Cancer types
  • Lung
Title of study
A multicentre single arm phase II trial assessing the efficacy of immunotherapy, chemotherapy and stereotactic radiotherapy to metastases followed by definitive surgery or radiotherapy to the primary tumour, in patients with synchronous oligo-metastatic non small cell lung cancer
Version Number
Approval Date 
1, 20 April 2020
Short Title
CHESS
Study site
Principle Investigator
L. Hendriks, MUMC
Investigator Maastro
prof dr D. de Ruysscher
Sponsor
ETOP
Trial registry
Objectives 

The objective of this trial is to evaluate PFS in synchronous oligometastatic NSCLC patients treated with induction immunotherapy, chemotherapy and SBRT to all metastases followed by definitive surgery or radiotherapy to the locoregional primary tumour.

Primary Endpoint 

Progression-free survival at 12 months.

Secondary Endpoints 

– Overall survival
– Pattern of disease progression
– Distant progression-free survival
– Response to induction therapy
– Overall response
– Duration of response
– Toxicity before and after surgery/radiotherapy
– Symptom-specific and global quality of life